Informational only — Not medical advice. Always consult a licensed healthcare provider.

Shasthya স্বাস্থ্য · Health, made simple
বাং
Community data Updated 2 months ago

Tranexamic Acid

Anti-fibrinolytic drugs Prescription
Check interactions
🌐 বাংলায় দেখুন

Indications

Cancer

Tranexamic Acid is used to prevent and treat bleeding in several areas of medicine. General medicine: haemophtoes, digestive haemorrhages, haemorrhagic syndromes in leukaemia, cirrhosis and haemophilia, thrombocytopenic purpura, and accidents during thrombolytic therapy and transfusion. Surgery: prevention and antihaemorrhagic treatment during operations of any type and nature, particularly pulmonary, cardiovascular and abdominal surgery, and also post-operative and traumatic shock. Urology: prevention and antihaemorrhagic treatment in prostatic, vesical and renal surgery, and for haematurias. Obstetrics: prevention and treatment of post-partum and puerperium haemorrhages, haemorrhagic metrophathies, functional menometrorrhagias, and idiopathic or IUD (intra uterine device) induced menorrhagias. It is also used for primitive hyperfibrinolysis (abruptio placentae, premature placenta detachment) and in cervical conization. Otorhinolaryngology: prevention and antihaemorrhagic treatment during tonsillectomy, during specialist surgery generally, and for epistaxis. Stomatology: prevention and antihaemorrhagic treatment during maxillofacial operations and tooth extractions. Oncology (as supportive therapy): it promotes the formation of a fibrin capsule that walls off ovarian tumours and so inhibits their growth. It causes regression of ascites secondary to carcinoma. It also reduces bleeding during surgical interventions.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

This preparation contains tranexamic acid (trans-4 aminomethyl-cyclohexanecarboxylic acid). Tranexamic acid has a strong antifibrinolytic action, and in vivo and in vitro it has proved to be 10 times more active than conventional hemostatics, depending on the test.

Its antihemorrhagic action comes mainly from inhibiting the activation of plasminogen. This applies to exogenous activators like streptokinase and to endogenous ones like urokinase and the plasminogen tissue activator. That matters for clinical use, because it means Tranexamic Acid works against bleeding through an antifibrinolytic mechanism under many different conditions.

The acute toxicity of Tranexamic Acid is extremely low, and chronic toxicity is almost non-existent. It is well absorbed by the oral route, and the effect is already seen 15-30 minutes after administration. It is excreted mainly through the kidneys, but more slowly than conventional hemostatics, so its effect lasts longer. Because of this, considerably lower single doses can be given at greater intervals, and the plasma level doesn't drop to an ineffective antifibrinolytic level between one dose and the next.

At therapeutic doses, Tranexamic Acid does not interfere with the clotting process. Even prolonged administration has not been seen to bring any tendency to thrombophilia.

Pregnancy & Breastfeeding

Since it is not known whether the drug crosses the placenta or what effect it might have on a developing baby, Tranexamic Acid should not be given during known or suspected pregnancy. Tranexamic Acid does pass into breast milk, but only at roughly one hundredth of the concentration found in the mother's blood, so it is unlikely to have any antifibrinolytic effect on the infant.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Adults: The usual dose is 500 to 1000 mg, three times daily. For prophylaxis, the mean recommended daily dose is 0.5 to 1 gm by mouth, or 500 mg by the parenteral (intravenous or intramuscular) route. For treatment of hemorrhagic manifestations, the oral dose is increased to 1 to 3 gm given in divided doses. In cases of particular seriousness and urgency, treatment may begin with an ampoule (500 mg) injected slowly by the intravenous route, followed by the necessary oral doses. Children: For prophylaxis, 5 to 10 mg for every kg of body weight is given orally each day in divided doses. For therapeutic purposes, the oral dose is doubled, from 10 to 20 mg/kg, while intravenous or intramuscular treatment is begun with 10 mg/kg (equal to 0.5 ml for every 5 kg) given slowly by the intravenous route, continuing with oral doses up to the amount required. Where more convenient, such as in small babies, the ampoules may be diluted in a little sweetened water and given orally instead of the capsules. Elderly patients: No reduction in dosage is necessary unless there is evidence of renal failure.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.